회사 개요
Galapagos NV is a biotechnology firm dedicated to developing medicines primarily within the oncology and immunology therapeutic areas, with a strategic focus on markets in the United States and Europe. The company operates within the broader Healthcare sector, specifically targeting the high-growth Biotechnology industry where innovation in drug discovery and clinical development defines competitive advantage. Currently, the company holds a market capitalization of $1.92B and generates annual revenue of $1.11B, though the specific employee count is not publicly disclosed in the available data. These valuation and revenue metrics indicate that Galapagos NV possesses a significant market presence, positioning it as a substantial entity capable of funding extensive research and development programs while maintaining a robust balance sheet relative to its peers in the biotech space.
재무 건전성
The company reported a trailing twelve-month revenue of $1.11B accompanied by a net income of $319.49M and an EBITDA of $568.17M, illustrating a highly efficient cost structure where operating expenses are significantly lower than total revenue generation. Free cash flow stands at $344.64M, which provides the organization with substantial financial flexibility to fund future clinical trials, acquire assets, or return capital without relying on external financing. Profitability analysis reveals a gross margin of 56.0%, an operating margin of 88.0%, and a profit margin of 28.8%, indicating exceptional operational leverage and pricing power typical of late-stage biotechnology assets nearing commercialization. The balance sheet demonstrates a conservative financial posture with $3.00B in cash against a negligible debt load of $6.92M, resulting in a debt-to-equity ratio of 0.21 that suggests minimal leverage risk. Short-term liquidity is exceptionally strong, evidenced by a current ratio of 20.14, which implies the company holds far more current assets than current liabilities and can easily meet its short-term obligations. Furthermore, the Return on Equity of 10.4% and Return on Assets of 8.9% highlight effective management in generating returns on the capital invested, a critical metric for capital-intensive industries like biotechnology.
밸류에이션 평가
Valuation metrics show a Trailing P/E ratio of 5.04 compared to a Forward P/E of -18.18, a discrepancy that implies the market is pricing in future earnings volatility or potential losses in upcoming periods despite current profitability. The Price to Book ratio is recorded at 0.50, suggesting the stock trades at half its book value, which may indicate market skepticism regarding the immediate monetization of its pipeline or a premium discount for the inherent risks of drug development. Alternative valuation measures such as a Price to Sales ratio of 1.72 and an EV/EBITDA of -1.95 provide context for the stock's pricing relative to its revenue generation and earnings before interest, taxes, depreciation, and amortization. In terms of trading range, the stock has a 52-week high of $37.78 and a 52-week low of $23.23, with the current price position requiring calculation relative to these bounds to determine the percentage distance from the recent highs. The Beta value is 0.15, which signifies that the stock's price volatility is significantly lower than the broader market, making it a defensive position relative to the overall equity market fluctuations.
Growth & Income
Galapagos NV demonstrates aggressive expansion with a Revenue Growth of 1093.2% year-over-year and an Earnings Growth of 3036.0% year-over-year, indicating that earnings are growing at a pace far exceeding revenue growth, which often points to economies of scale or significant cost efficiencies realized in the current fiscal period. As a non-dividend payer, the company maintains a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning that instead of distributing cash to shareholders, the firm reinvests its substantial earnings into research, development, and commercialization efforts to accelerate growth. This strategy of retaining earnings is common in biotechnology where capital allocation towards pipeline advancement is prioritized over immediate income generation for investors. Overall, the company presents a profile characterized by explosive revenue and earnings expansion, coupled with a disciplined financial management approach that forgoes dividends to fuel long-term value creation through its oncology and immunology pipeline.